Docetaxel-based chemotherapy promotes the intratumor infiltration of T cells and upregulates the abundance of PD-1 and PD-L1 in mouse tumor transplantation model, thereby sensitizing tumor to anti-PD1 blockers (76). This evidence concerns the gene CD274 and neoplasm.